Pharma News
Pharmaceutical
Swiss pharma giant Novartis today announced that the US Food and Drug Administration (FDA) has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. 17 July 2026
Pharmaceutical
US pharma major Eli Lilly has agreed to acquire AtaiBeckley in a deal worth up to $3.8 billion in one of the largest big pharma moves yet into psychedelic-based mental health medicines. 16 July 2026
Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with Shanghai-based Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. 14 July 2026
Most Read
Recent news
Pharmaceutical
Last week saw AstraZeneca sign an accord with China’s Dizal Pharmaceutical for rights to the latter’s lung cancer drug Zegfrovy. Biogen released new Phase II data its Alzheimer’s candidate diranersen that raised questions. Celcuity won US Food and Drug Administration (FDA) for its investigational breast cancer drug Revtorpyk and Merck & Co announced FDA approval for its oral PCK9 cholesterol drug Lipfendra. Eli Lilly revealed plans to acquire mental health biotech AtaiBeckley for an upfront $2.8 billion. 19 July 2026
Pharmaceutical
Australia’s CSL Limited subsidiary CSL Seqirus has started shipping influenza vaccines to health care providers in the USA, helping them get prepared for the upcoming flu season, to target the H3N2 subclade K strain that drove last season’s historic surge. 18 July 2026
Pharmaceutical
The US Food and Drug Administration’s (FDA) approval of Utebzi (tebipenem pivoxil) gives physicians the first oral carbapenem option for adults with complicated urinary tract infections (cUTIs), including pyelonephritis, who have limited or no alternative oral treatment options. 17 July 2026
Pharmaceutical
Swiss pharma giant Novartis today announced that the US Food and Drug Administration (FDA) has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. 17 July 2026
Pharmaceutical
UK pharma major GSK today provided an update on the CALM-1 and CALM-2 Phase III clinical trials, which assessed the efficacy and safety of two doses of camlipixant (a P2X3 receptor antagonist) in adults with refractory chronic cough (RCC). RCC is a complex and under-recognised disease with limited treatment options. 17 July 2026
Refine search
In Brief
Pharmaceutical
7 July 2026 Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions.
Pharmaceutical
4 July 2026 India’s Orchid Pharma is in advanced negotiations to out-license its breakthrough antibiotic enmetazobactam in the USA, a move that could mark the company’s commercial entry into the world’s largest pharmaceutical market.
Insights
Pharmaceutical
Latin American countries need to treat health spending as an investment rather than a cost if they are to expand coverage, strengthen health systems and support broader economic development, according to the Latin American Federation of the Pharmaceutical Industry, FIFARMA. 16 July 2026
Pharmaceutical
A Q&A with Iris Zemzoum, President of Europe Region at Novartis, who believes Europe can no longer separate industrial policy, healthcare policy and patient outcomes into different conversations. 16 July 2026
Pharmaceutical
Much of the recent conversation in biopharma has centered on complex new treatments. Antibody-drug conjugates (ADC), cell therapies, gene therapies, radiopharmaceuticals, RNA medicines and bispecific antibodies have drawn the capital, the partnerships and the headlines. 16 July 2026
Pharmaceutical
Leading Russian drugmakers are considering accelerating their expansion into the African region this year that will take place through the supplies of their drugs to the continent and building of their production facilities there, reports The Pharma Letter’s local correspondent. 13 July 2026
Pharmaceutical
The Russian Supreme Court has refused to review the dispute of UK pharma major AstraZeneca with the Russian drugmaker Akrikhin dispute over Forxiga (dapagliflozin) - a drug for the treatment of type 2 diabetes – that became a response to the cassation appeal, which was earlier filed by AstraZeneca. 6 July 2026
Pharmaceutical
Russian pharmaceutical companies and global drugmakers operating in the local market have called on the national government to speed the process of entering new drugs in public procurements after their registration, reports The Pharma Letter’s local correspondent. 3 July 2026
Pharmaceutical
Eastern Europe has long been part of global clinical development, although it is more often covered when disruption affects trial delivery. Russia’s invasion of Ukraine in February 2022 made that pattern more visible. Sponsors, contract research organizations and regulators had to reassess trial continuity, patient retention, site access, medicine supply, sample movement and missing data. 3 July 2026
Boardroom
Pharmaceutical
UK headquartered ProAxsis, a commercial protease biomarker-led research company supporting drug development and clinical research through specialist biomarker insights in the respiratory clinical development space, has completed a major corporate repositioning and reorganization. The move marks the next stage of the company's development. 14 July 2026
Pharmaceutical
US pharma major Pfizer has changed the leadership of its obesity discovery group, with Danna Breen appointed vice president and head of obesity discovery following the departure of longtime scientific leader Kendra Bence. 13 July 2026
Pharmaceutical
San Diego, USA-based ARS Pharmaceuticals has announced a chief executive (CEO) succession, in which co-founder and CEO Richard Lowenthal will no longer serve as an employee and officer of the company effective July 6, 2026. 9 July 2026
Pharmaceutical
Dutch contract research, development and manufacturing organization (CRDMO) Symeres and Axxam, a provider of biology-driven discovery services, today announced the appointment of Russell Thomas as chief scientific officer to drive a joint collaboration between Symeres and Axxam that combines the unique R&D services offering of both organizations. 8 July 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze